Page 156 - Read Online

Page 24 Spiliopoulou et al. Cancer Drug Resist 2024;7:2 https://dx.doi.org/10.20517/cdr.2023.46

163. Maio M, Blank C, Necchi A, et al. Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: the
future is now! Eur J Cancer 2021;152:155-64. DOI
164. Peña-Asensio J, Calvo H, Torralba M, Miquel J, Sanz-de-Villalobos E, Larrubia JR. Anti-PD-1/PD-L1 based combination
+
immunotherapy to boost antigen-specific CD8 T cell response in hepatocellular carcinoma. Cancers 2021;13:1922. DOI PubMed
PMC
165. Gianchecchi E, Fierabracci A. Inhibitory receptors and pathways of lymphocytes: the role of PD-1 in Treg development and their
involvement in autoimmunity onset and cancer progression. Front Immunol 2018;9:2374. DOI PubMed PMC
166. Moore DC, Elmes JB, Shibu PA, Larck C, Park SI. Mogamulizumab: an anti-CC chemokine receptor 4 antibody for T-cell
lymphomas. Ann Pharmacother 2020;54:371-9. DOI PubMed
167. Orcutt-Jahns BT, Emmel PC, Snyder EM, Taylor SD, Meyer AS. Multivalent, asymmetric IL-2-Fc fusions show enhanced selectivity
for regulatory T cells. Sci Signal 2023;16:eadg0699. DOI PubMed PMC
168. Fattori S, Le Roy A, Houacine J, et al. CD25high effector regulatory T cells hamper responses to PD-1 blockade in triple-negative
breast cancer. Cancer Res 2023;83:3026-44. DOI PubMed PMC
169. Simonelli M, Garralda E, Eskens F, et al. Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase
I/II, open-label, multicenter study. ESMO Open 2022;7:100562. DOI PubMed PMC
170. Tsang K, Fantini M, Cole C, Annunziata C, Arlen P. A therapeutic humanized anti-carcinoma monoclonal antibody (mAb) can also
identify immunosuppressive regulatory T (Tregs) cells and down regulate Treg-mediated immunosuppression. J Immunother Cancer
2021;9:A881. DOI
171. García-Díaz N, Wei Q, Taskén K. Small molecule inhibitors targeting regulatory T cells for cancer treatment. Eur J Immunol
;2023:e2350448. DOI PubMed
172. Li JY, Duan XF, Wang LP, et al. Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell
lung cancer. J Immunol Res 2014;2014:286170. DOI PubMed PMC
173. Deng B, Yang B, Chen J, et al. Gallic acid induces T-helper-1-like T cells and strengthens immune checkpoint blockade efficacy. J
reg
Immunother Cancer 2022;10:e004037. DOI PubMed PMC
174. Marshall LA, Marubayashi S, Jorapur A, et al. Tumors establish resistance to immunotherapy by regulating T recruitment via
reg
CCR4. J Immunother Cancer 2020;8:e000764. DOI PubMed PMC
175. Ketcham JM, Marshall LA, Talay O. CCR4 antagonists inhibit T trafficking into the tumor microenvironment. ACS Med Chem Lett
reg
2018;9:953-5. DOI PubMed PMC
176. Yoshie O. CCR4 as a therapeutic target for cancer immunotherapy. Cancers 2021;13:5542. DOI PubMed PMC
177. Lim EL, Okkenhaug K. Phosphoinositide 3-kinase δ is a regulatory T-cell target in cancer immunotherapy. Immunology
2019;157:210-8. DOI PubMed PMC
+
178. Ahmad S, Abu-Eid R, Shrimali R, et al. Differential PI3Kδ signaling in CD4 T-cell subsets enables selective targeting of T
regulatory cells to enhance cancer immunotherapy. Cancer Res 2017;77:1892-904. DOI
179. Kirkwood JM, Iannotti N, Cho D, et al. Abstract CT176: effect of JAK/STAT or PI3Kδ plus PD-1 inhibition on the tumor
microenvironment: biomarker results from a phase Ib study in patients with advanced solid tumors. Cancer Res 2018;78:CT176. DOI
180. Borazanci E, Pishvaian MJ, Nemunaitis J, Weekes C, Huang J, Rajakumaraswamy N. A phase Ib study of single-agent idelalisib
followed by idelalisib in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma. Oncologist
2020;25:e1604-13. DOI PubMed PMC
181. Haselmayer P, Camps M, Muzerelle M, et al. Characterization of novel PI3Kδ inhibitors as potential therapeutics for SLE and lupus
nephritis in pre-clinical studies. Front Immunol 2014;5:233. DOI PubMed PMC
182. Johnson Z, Tarantelli C, Civanelli E, et al. IOA-244 is a non-ATP-competitive, highly selective, tolerable PI3K delta inhibitor that
targets solid tumors and breaks immune tolerance. Cancer Res Commun 2023;3:576-91. DOI PubMed PMC
183. Di Giacomo AM, Santangelo F, Amato G, et al. First-in-human (FIH) phase I dose escalation study (part A) of the first oral allosteric
modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) roginolisib in patients with advanced cancer and dose confirmation in
uveal melanoma (part B). J Clin Oncol 2023;41:3110. DOI
184. Schreiber SL. The rise of molecular glues. Cell 2021;184:3-9. DOI PubMed
185. Bonazzi S, d'Hennezel E, Beckwith REJ, et al. Discovery and characterization of a selective IKZF2 glue degrader for cancer
immunotherapy. Cell Chem Biol 2023;30:235-47.e12. DOI
186. Munn DH, Sharma MD, Johnson TS. Treg destabilization and reprogramming: implications for cancer immunotherapy. Cancer Res
2018;78:5191-9. DOI PubMed PMC
187. Dixon ML, Leavenworth JD, Leavenworth JW. Lineage reprogramming of effector regulatory T cells in cancer. Front Immunol
2021;12:717421. DOI PubMed PMC
188. Ayala MA, Li Z, DuPage M. Treg programming and therapeutic reprogramming in cancer. Immunology 2019;157:198-209. DOI
PubMed PMC
189. Keller P, Mazo I, Gao Y, et al. Abstract P106: reprogramming regulatory T cells (Treg) using a MALT1 inhibitor for cancer therapy.
Mol Cancer Ther 2021;20:P106. DOI
190. Naing A, Park J, Klempner S, et al. 1033P first-in-human study of MALT1 inhibitor MPT-0118: results from monotherapy dose
escalation in advanced or metastatic refractory solid tumors. Ann Oncol 2023;34:S627-8. DOI
+ +
191. Perez SA, Karamouzis MV, Skarlos DV, et al. CD4 CD25 regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-